Patent ID: 11878028
Assignee: HENAN GENUINE BIOTECH CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 1:
2. The pharmaceutical composition according to claim 1, wherein, the EGFR/TKI inhibitor is selected from the group consisting of osimertinib, gefitinib, erlotinib, doxitinib, olmutinib, icotinib, pyrotinib, dacomitinib, afatinib, neratinib, lapatinib, ABT-414, varlitinib, HLX-07, tesevatinib, theliatinib, epaltinib succinate, S-222611, furmonertinib, befotertinib, rezivertinib, poziotinib and a combination thereof.